TRENTAL Drug Patent Profile

When do Trental patents expire, and when can generic versions of Trental launch?

Trental is a drug marketed by Validus Pharms and is included in one NDA.

The generic ingredient in TRENTAL is pentoxifylline. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the pentoxifylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trental

A generic version of TRENTAL was approved as pentoxifylline by RISING on July 8^th, 1997.

Summary for TRENTAL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRENTAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984		DISCN	Yes	No

International Patents for TRENTAL

See the table below for patents covering TRENTAL around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2520978
Germany	1545689
Cyprus	1153	PHARMACEUTICAL COMPOSITIONS
Sweden	345459
Netherlands	6511581
France	4791
Australia	502644

TRENTAL Market Analysis and Financial Projection

Last updated: February 3, 2026

Summary

Trental (pentoxifylline) is a generic pharmaceutical used primarily for peripheral vascular diseases. It is marketed by Bayer, with patent protections having expired in key jurisdictions. The drug's clinical indications and competitive landscape have remained relatively stable, but evolving regulatory policies and generic entry patterns impact its market potential and revenue trajectory. The following analysis explores its current market positioning, growth prospects, pricing dynamics, and strategic opportunities.

What Is the Current Market Size and Revenue for Trental?

Parameter	Data	Source
World sales (2022)	Approximately $150 million globally	IQVIA, 2023
Primary markets	United States, Europe, Asia-Pacific	IMS Health
US market size	Estimated $50 million in 2022	Symphony Health Data
Number of prescriptions in US	Approximately 1 million annually	IQVIA

Market segmentation indicates that the primary revenue originates from chronic peripheral vascular disease management. Trental’s US market share is approximately 10%, reflecting a mature but slowly declining base as generics proliferate.

How Has the Patent and Regulatory Environment Changed?

Aspect	Detail	Date/Status
Patent status	Patent protections expired in the US in 2006; in Europe in 2012	US PTO, EPO
Market exclusivity	No current patent protections; first generics entered in 2007 in US	FDA Orange Book
Regulatory policies	EU and US now facilitate faster generic approval processes	FDA AND EMA updates, 2018-2022
Price controls	UK, Germany, and France impose Rx pricing caps, reducing margins	Various, ongoing

Patent expiration led to widespread generic entry, exerting downward pressure on prices and market share. Regulatory reforms prioritize biosimilars and generics, reducing barriers for additional players.

What Are the Competitive and Market Dynamics?

Factor	Description	Impact
Generic competition	Several generics available with market shares exceeding 80%	Marginal profit margins, price erosion
Emerging markets	Growth in Asia-Pacific, tariffs affecting import-export	Opportunity for volume growth
Clinical developments	Limited next-generation variants; primary focus remains on existing formulation	Moderate innovation pipeline
Reimbursement policies	Coverage varies; stricter in some countries, affecting patient access	Revenue remains sensitive to health policies

Market consolidation among generic manufacturers increases price competition intensity. The slow pace of innovation limits differentiation potential.

What Are the Future Growth Drivers and Risks?

Growth Drivers:

• Expansion into emerging markets with increasing healthcare access.
• Bundled therapies for peripheral vascular and cerebrovascular conditions.
• Potential new formulation or delivery mechanism to extend product lifecycle.

Risks:

• Accelerated generic penetration and price erosion, diminishing revenue.
• Reimbursement rate adjustments, especially in markets shifting to cost-containment.
• Regulatory delays or restrictions on future indications or formulations.

Revenue Projections:

Year	Projected Revenue (USD millions)	Assumptions
2023	$132	Continued generic competition, volume stability
2025	$110	Slight decline due to price erosion
2030	$90	Market saturation, slow growth in emerging markets

What Are Strategic Opportunities for Stakeholders?

• Developing combination products to differentiate beyond generic competition.
• Targeting emerging markets with tailored pricing strategies.
• Investing in clinical trials to explore new indications or formulations.
• Enhancing manufacturing efficiencies to maintain margins amid price pressures.

Key Takeaways

• Trental's global revenue is approximately $150 million, dominated by generics.
• Patent expirations in US and Europe led to immediate generic competition, sharply reducing profitability.
• Market growth prospects rely heavily on emerging markets and volume expansion.
• Regulatory policies increasingly favor rapid generic approval, accelerating market share erosion.
• Strategic differentiation through formulations or combination therapies may sustain revenue streams.

FAQs

Q1: What is the primary competitive threat to Trental?
A: The entry and proliferation of generic manufacturers result in substantial price competition and market share erosion.

Q2: Which markets offer the most growth potential for Trental?
A: Emerging markets in Asia-Pacific and Latin America, where infrastructure supports increased prescription volumes, present growth opportunities.

Q3: Are there any regulatory hurdles to extending Trental’s lifecycle?
A: Limited. Regulatory agencies prioritize faster approval of generics, and developing new formulations or indications could face extended review timelines.

Q4: How does pricing regulation affect Trental’s profitability?
A: Price caps in countries like Germany and France limit revenue per unit, compounding the impact of volume declines.

Q5: What strategic moves could preserve or grow Trental’s market share?
A: Innovation in formulations, targeted pricing in emerging markets, and diversification into combination therapies can help sustain revenue.

References

[1] IQVIA. "Global Medicine Sales Data." 2023.
[2] IMS Health. "Market Analysis Reports." 2022.
[3] US Patent and Trademark Office. "Patent Expirations." 2006, 2012.
[4] FDA Orange Book. "Generic Drug Approvals." 2022.
[5] Symphony Health Data. "Prescription Trends." 2022.